InsiderTrades.com logo
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

KXS Insider Trading

Insider Ownership Percentage: 1.11%
Insider Buying (Last 12 Months): C$0.00
Insider Selling (Last 12 Months): C$11,495,771.60

Kinaxis Insider Trading History Chart

This chart shows the insider buying and selling history at Kinaxis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kinaxis Share Price & Price History

Current Price: C$151.27
Price Change: ▼ Price Decrease of -0.49 (-0.32%)
As of 11/28/2023 01:00 AM ET

This chart shows the closing price history over time for KXS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

Kinaxis Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2023Anne Gillian RobinsonSenior OfficerSell30,000C$152.50C$4,575,000.00
6/1/2023Pamela Sue PassmanDirectorSell5,649C$179.68C$1,015,027.57
5/19/2023Anne Gillian RobinsonSenior OfficerSell15,000C$184.00C$2,760,000.00
3/15/2023John Ernest SicardDirectorSell6,705C$169.47C$1,136,286.96
3/15/2023Paul CarreiroSenior OfficerSell1,447C$169.47C$245,221.06
3/8/2023Paul CarreiroSenior OfficerSell2,500C$172.08C$430,200.00
12/23/2022Michael David MaugerSenior OfficerSell4,000C$146.01C$584,036.00
12/21/2022Jay Allan MuelhoeferSenior OfficerSell5,000C$150.00C$750,000.005,215
11/22/2022James Alexander HollingworthSenior OfficerSell625C$146.91C$91,816.2547
11/14/2022Jay Allan MuelhoeferSenior OfficerSell10,000C$154.34C$1,543,426.005,215
9/20/2022Megan PatersonSenior OfficerSell5,000C$137.70C$688,493.001,613
9/12/2022Paul CarreiroSenior OfficerSell10,727C$143.73C$1,541,740.2233,329
9/9/2022Paul CarreiroSenior OfficerSell17,370C$143.05C$2,484,851.4529,591
9/2/2022Paul CarreiroSenior OfficerSell42,100C$144.13C$6,067,696.1823,512
8/18/2022Angel Luis MendezDirectorSell5,000C$165.00C$825,000.00
8/18/2022David Peter KellySenior OfficerSell1,768C$164.30C$290,484.17
6/10/2022Angel Luis MendezDirectorSell5,000C$131.77C$658,841.50
9/23/2021John Ernest SicardDirectorSell4,000C$195.97C$783,866.00280,864
9/15/2021Michael David MaugerSenior OfficerSell1,670C$200.00C$334,007.01
8/30/2021Paul CarreiroSenior OfficerSell3,300C$203.90C$672,864.063,855
8/26/2021Paul CarreiroSenior OfficerSell3,750C$197.00C$738,763.133,855
8/24/2021Paul CarreiroSenior OfficerSell1,752C$194.41C$340,610.003,855
8/11/2021Megan PatersonSenior OfficerSell5,000C$175.62C$878,116.504,608
6/23/2021Richard George MonkmanSenior OfficerSell4,400C$151.22C$665,382.0858,816
6/21/2021Richard George MonkmanSenior OfficerSell1,500C$150.90C$226,350.0082,316
12/10/2020John Ernest SicardDirectorSell18,374C$176.45C$3,242,092.30224,367
12/10/2020Richard George MonkmanSenior OfficerSell9,775C$176.45C$1,724,798.7523,816
11/30/2020Richard George MonkmanSenior OfficerSell25,000C$191.11C$4,777,790.0023,816
See Full Table
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Kinaxis (TSE:KXS)

51.15% of Kinaxis stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Kinaxis logo
Kinaxis Inc. provides cloud-based subscription software for supply chain operations in the United States, Japan, Hong Kong, The Netherlands, South Korea, the United Kingdom, Singapore, Romania, France, Ireland, Germany, India, and Canada. It offers Kinaxis, a cloud-based platform, which provides advanced planning, sales and operations planning, supply and demand planning, inventory management, and command and control center services. The company also provides professional services, including business transformation, implementation, and continuous learning services; and support services. It serves aerospace and defense, automotive, consumer products, high-tech and electronics, industrial, life sciences, and retail markets. The company was formerly known as webPLAN Inc. and changed its name to Kinaxis Inc. in May 2005. Kinaxis Inc. was founded in 1984 and is headquartered in Ottawa, Canada.
Read More on Kinaxis

Today's Range

Now: C$151.27
Low: C$151.00
High: C$152.74

50 Day Range

MA: C$145.98
Low: C$131.12
High: C$159.43

52 Week Range

Now: C$151.27
Low: C$129.13
High: C$191.80

Volume

79,631 shs

Average Volume

62,225 shs

Market Capitalization

C$4.31 billion

P/E Ratio

216.10

Dividend Yield

N/A

Beta

0.84

Who are the company insiders with the largest holdings of Kinaxis?

Kinaxis' top insider shareholders include:
  1. Paul Carreiro (Senior Officer)
  2. Jay Allan Muelhoefer (Senior Officer)
  3. Megan Paterson (Senior Officer)
  4. James Alexander Hollingworth (Senior Officer)
  5. Angel Luis Mendez (Director)
  6. Anne Gillian Robinson (Senior Officer)
  7. David Peter Kelly (Senior Officer)
  8. John Ernest Sicard (Director)
  9. Michael David Mauger (Senior Officer)
  10. Pamela Sue Passman (Director)
Learn More about top insider investors at Kinaxis.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.